218
Participants
Start Date
March 28, 2013
Primary Completion Date
July 18, 2018
Study Completion Date
July 18, 2018
Anifrolumab
Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
Research Site, Chiayi City
Research Site, Sofia
Research Site, Plovdiv
Research Site, New York
Research Site, Lima
Research Site, Suwon
Research Site, Vinnytsia
Research Site, Vinnitsya
Research Site, Raleigh
Research Site, Charlotte
Research Site, Atlanta
Research Site, Stockbridge
Research Site, Orlando
Research Site, Tampa
Research Site, Ocala
Research Site, Birmingham
Research Site, Memphis
Research Site, Columbus
Research Site, Indianapolis
Research Site, Chicago
Research Site, Tulsa
Research Site, Houston
Research Site, Houston
Research Site, Las Cruces
Research Site, La Palma
Research Site, Long Beach
Research Site, Upland
Research Site, Palm Desert
Research Site, Spokane
Research Site, Iași
Research Site, Los Angeles
Research Site, Rio de Janeiro
Research Site, São Paulo
Research Site, Barranquilla
Research Site, Bogotá
Research Site, Bucaramanga
Research Site, Chía
Research Site, Medellín
Research Site, Brno
Research Site, Prague
Research Site, Debrecen
Research Site, Guadalajara
Research Site, León
Research Site, México
Research Site, Toluca
Research Site, Arequipa
Research Site, Lima
Research Site, Gwangju
Research Site, Seodaemun-gu
Research Site, Zhongzheng District
Research Site, Donetsk
Research Site, Kyiv
Research Site, Ternopil
Research Site, Bialystok
Research Site, Krakow
Research Site, Nadarzyn
Research Site, Poznan
Lead Sponsor
MedImmune LLC
INDUSTRY